📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. (2015)

First Author: Cortes J

Attributed to: Infrastructure for collaboration: Leeds MRC Medical Bioinformatics Centre funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1007/s10549-015-3633-7

PubMed Identifier: 26567010

Publication URI: http://europepmc.org/abstract/MED/26567010

Type: Journal Article/Review

Volume: 154

Parent Publication: Breast cancer research and treatment

Issue: 3

ISSN: 0167-6806